Two-year follow-up of transcatheter aortic valve replacement in low-risk patients with symptomatic severe bicuspid aortic valve stenosis.
bicuspid aortic valve
low surgical risk
transcatheter aortic valve replacement
Journal
Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions
ISSN: 1522-726X
Titre abrégé: Catheter Cardiovasc Interv
Pays: United States
ID NLM: 100884139
Informations de publication
Date de publication:
07 Aug 2024
07 Aug 2024
Historique:
revised:
30
06
2024
received:
05
01
2024
accepted:
20
07
2024
medline:
7
8
2024
pubmed:
7
8
2024
entrez:
7
8
2024
Statut:
aheadofprint
Résumé
In 2019, the US Food and Drug Administration (FDA) approved transcatheter aortic valve replacement (TAVR) for low-risk patients with symptomatic severe tricuspid aortic stenosis. However, bicuspid aortic valve (BAV) patients were included only in single-arm registries of pivotal low-risk TAVR trials, resulting in limited data for this subgroup. The LRT (Low Risk TAVR) trial was an investigator-initiated, prospective, multicenter study and the first FDA-approved investigational device exemption trial to evaluate the feasibility of TAVR with balloon-expandable or self-expanding valves in low-risk patients with symptomatic severe BAV stenosis. This analysis reports 2-year follow-up, assessing the primary outcome of all-cause mortality and evaluating clinical outcomes. From 2016 to 2019, a total of 72 low-risk patients diagnosed with symptomatic, severe BAV stenosis underwent TAVR across six centers. Six patients were lost to follow-up. At 2-year follow-up, mortality was 1.5% (1 of 66 patients). Among the remaining 65 patients, four experienced nondisabling strokes (6.2%), while 2 (3.1%) developed infective endocarditis. No new permanent pacemakers were required beyond the 30-day follow-up, and no patients, including those with endocarditis, needed aortic valve re-intervention. At the 2-year echocardiography follow-up (n = 65), 27.8% of BAV patients showed mild aortic regurgitation, with none exhibiting moderate or severe regurgitation. The mean aortic gradient was 12.1 ± 4.1 mmHg, and the mean valve area was 1.7 ± 0.5 cm². The 2-year follow-up confirms commendable clinical outcomes of TAVR in patients with bicuspid aortic stenosis, establishing its evident safety.
Sections du résumé
BACKGROUND
BACKGROUND
In 2019, the US Food and Drug Administration (FDA) approved transcatheter aortic valve replacement (TAVR) for low-risk patients with symptomatic severe tricuspid aortic stenosis. However, bicuspid aortic valve (BAV) patients were included only in single-arm registries of pivotal low-risk TAVR trials, resulting in limited data for this subgroup.
METHODS
METHODS
The LRT (Low Risk TAVR) trial was an investigator-initiated, prospective, multicenter study and the first FDA-approved investigational device exemption trial to evaluate the feasibility of TAVR with balloon-expandable or self-expanding valves in low-risk patients with symptomatic severe BAV stenosis. This analysis reports 2-year follow-up, assessing the primary outcome of all-cause mortality and evaluating clinical outcomes.
RESULTS
RESULTS
From 2016 to 2019, a total of 72 low-risk patients diagnosed with symptomatic, severe BAV stenosis underwent TAVR across six centers. Six patients were lost to follow-up. At 2-year follow-up, mortality was 1.5% (1 of 66 patients). Among the remaining 65 patients, four experienced nondisabling strokes (6.2%), while 2 (3.1%) developed infective endocarditis. No new permanent pacemakers were required beyond the 30-day follow-up, and no patients, including those with endocarditis, needed aortic valve re-intervention. At the 2-year echocardiography follow-up (n = 65), 27.8% of BAV patients showed mild aortic regurgitation, with none exhibiting moderate or severe regurgitation. The mean aortic gradient was 12.1 ± 4.1 mmHg, and the mean valve area was 1.7 ± 0.5 cm².
CONCLUSION
CONCLUSIONS
The 2-year follow-up confirms commendable clinical outcomes of TAVR in patients with bicuspid aortic stenosis, establishing its evident safety.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : MedStar Health Research Institute
Informations de copyright
© 2024 Wiley Periodicals LLC.
Références
Mack MJ, Leon MB, Thourani VH, et al. Transcatheter aortic‐valve replacement with a balloon‐expandable valve in low‐risk patients. N Engl J Med. 2019;380:1695‐1705.
Popma JJ, Deeb GM, Yakubov SJ, et al. Transcatheter aortic‐valve replacement with a Self‐expanding valve in low‐risk patients. N Engl J Med. 2019;380:1706‐1715.
Vincent F, Ternacle J, Denimal T, et al. Transcatheter aortic valve replacement in bicuspid aortic valve stenosis. Circulation. 2021;143:1043‐1061.
Zhang Y, Xiong T‐Y, Li Y‐M, et al. Patients with bicuspid aortic stenosis undergoing transcatheter aortic valve replacement: a systematic review and meta‐analysis. Front Cardiovasc Med. 2022;9:794850.
Felberbaum M. FDA expands indication for several transcatheter heart valves to patients at low risk for death or major complications associated with open‐heart surgery. Accessed July 5, 2023. https://www.fda.gov/news-events/press-announcements/fda-expands-indication-several-transcatheter-heart-valves-patients-low-risk-death-or-major
Makkar RR, Yoon SH, Chakravarty T, et al. Association between transcatheter aortic valve replacement for bicuspid vs tricuspid aortic stenosis and mortality or stroke among patients at low surgical risk. JAMA. 2021;326:1034‐1044.
Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American heart association joint committee on clinical practice guidelines. Circulation. 2021;143:e72‐e227.
Waksman R, Rogers T, Torguson R, et al. Transcatheter aortic valve replacement in low‐risk patients with symptomatic severe aortic stenosis. J Am Coll Cardiol. 2018;72:2095‐2105.
Waksman R, Corso PJ, Torguson R, et al. TAVR in Low‐Risk patients. JACC Cardiovas Intervent. 2019;12:901‐907.
Waksman R, Craig PE, Torguson R, et al. Transcatheter aortic valve replacement in low‐risk patients with symptomatic severe bicuspid aortic valve stenosis. JACC Cardiovas Intervent. 2020;13:1019‐1027.
Rogers T, Torguson R, Bastian R, Corso P, Waksman R. Feasibility of transcatheter aortic valve replacement in low‐risk patients with symptomatic severe aortic stenosis: rationale and design of the low risk TAVR (LRT) study. Am Heart J. 2017;189:103‐109.
Sievers HH, Schmidtke C. A classification system for the bicuspid aortic valve from 304 surgical specimens. J Thorac Cardiovasc Surg. 2007;133:1226‐1233.
Jilaihawi H, Asch FM, Manasse E, et al. Systematic CT methodology for the evaluation of subclinical leaflet thrombosis. JACC Cardiovas Imag. 2017;10:461‐470.
Waksman R, Bhogal S, Gordon P, et al. Transcatheter aortic valve replacement and impact of subclinical leaflet thrombosis in low‐risk patients: LRT trial 4‐year outcomes. Circ Cardiovas Intervent. 2023;16:e012655.
Kappetein AP, Head SJ, Généreux P, et al. Updated standardized endpoint definitions for transcatheter aortic valve implantation. J Am Coll Cardiol. 2012;60:1438‐1454.
VARC‐3 Writing Committee, Piazza N, Généreux, P, Alu MC, Nazif T, et al. Valve academic research consortium 3: updated endpoint definitions for aortic valve clinical research. J Am Coll Cardiol. 2021;77:2717‐2746.
Medranda GA, Rogers T, Doros G, et al. Transcatheter aortic valve replacement in Low‐Risk bicuspid and tricuspid patients: meta‐analysis. Cardiovas Revascularizat Med. 2021;33:1‐6.
Du Y, Wang Z, Liu W, et al. Transcatheter aortic valve implantation in sievers type 0 vs. type 1 bicuspid aortic valve morphology: systematic review and meta‐analysis. Front Cardiovasc Med. 2021;8:771789.
Philip F, Faza NN, Schoenhagen P, et al. Aortic annulus and root characteristics in severe aortic stenosis due to bicuspid aortic valve and tricuspid aortic valves: implications for transcatheter aortic valve therapies. Catheter Cardiovasc Interv. 2015;86:E88‐E98.
Tchetche D, de Biase C, van Gils L, et al. Bicuspid aortic valve anatomy and relationship with devices: the BAVARD multicenter registry. Circ Cardiovas Intervent. 2019;12:e007107.
Costa G, Angelillis M, Petronio AS. Bicuspid valve sizing for transcatheter aortic valve implantation: the missing link. Front Cardiovasc Med. 2022;8:770924.
Khan A, Aslam A, Satti KN, Ashiq S. Infective endocarditis post‐transcatheter aortic valve implantation (TAVI), microbiological profile and clinical outcomes: a systematic review. PLoS One. 2020;15:e0225077.
Leon MB, Mack MJ, Hahn RT, et al. Outcomes 2 years after transcatheter aortic valve replacement in patients at low surgical risk. J Am Coll Cardiol. 2021;77:1149‐1161.
Yoon SH, Kim WK, Dhoble A, et al. Bicuspid aortic valve morphology and outcomes after transcatheter aortic valve replacement. J Am Coll Cardiol. 2020;76:1018‐1030.
Deeb GM, Reardon MJ, Ramlawi B, et al. Propensity‐matched 1‐Year outcomes following transcatheter aortic valve replacement in low‐risk bicuspid and tricuspid patients. JACC Cardiovas Intervent. 2022;15:511‐522.
Mentias A, Feng K, Alashi A, et al. Long‐term outcomes in patients with aortic regurgitation and preserved left ventricular ejection fraction. J Am Coll Cardiol. 2016;68:2144‐2153.
Forrest JK, Kaple RK, Ramlawi B, et al. Transcatheter aortic valve replacement in bicuspid versus tricuspid aortic valves from the STS/ACC TVT registry. JACC Cardiovas Intervent. 2020;13:1749‐1759.
Wijesinghe N, Ye J, Rodés‐Cabau J, et al. Transcatheter aortic valve implantation in patients with bicuspid aortic valve stenosis. JACC Cardiovas Intervent. 2010;3:1122‐1125.
Cave DGW, Panayiotou H, Bissell MM. Hemodynamic profiles before and after surgery in bicuspid aortic valve disease—a systematic review of the literature. Front Cardiovasc Med. 2021;8:629227.
Tchétché D, Ziviello F, De Biase C, et al. Transcatheter aortic valve implantation with the evolut platform for bicuspid aortic valve stenosis: the international, multicentre, prospective BIVOLUTX registry. EuroIntervention. 2023;19:502‐511.
Zahr F. Late‐breaking clinical science: three‐year outcomes from the evolut low risk tavr bicuspid study. TCTmd, 2023https://www.tctmd.com/slide/late-breaking-clinical-science-three-year-outcomes-evolut-low-risk-tavr-bicuspid-study
Williams MR, Jilaihawi H, Makkar R, et al. The PARTNER 3 bicuspid registry for transcatheter aortic valve replacement in Low‐Surgical‐Risk patients. JACC Cardiovas Intervent. 2022;15:523‐532.
Cannata S, Gandolfo C, Ribichini FL, et al. One‐year outcomes after transcatheter aortic valve implantation with the latest‐generation SAPIEN balloon‐expandable valve: the S3U registry. EuroIntervention. 2023;18:1418‐1427.
Nazif TM, Cahill TJ, Daniels D, et al. Real‐World experience with the SAPIEN 3 ultra transcatheter heart valve: a propensity‐matched analysis from the United States. Circ Cardiovas Intervent. 2021;14:e010543.
Jilaihawi H, Chen M, Webb J, et al. A bicuspid aortic valve imaging classification for the TAVR era. JACC Cardiovas Imag. 2016;9:1145‐1158.
Moroni F, Ziviello F, Federico F, et al. Transcatheter aortic bioprosthesis durability: a single‐center experience. Cardiovas Revascularizat Med. 2022;43:1‐6.